JPMorgan analyst Anupam Rama believes investor sentiment remains very low on Amicus Therapeutics' Phase 3 readout of zorblisa. The Phase 3 Essence data for the treatment of epidermolysis bullosa are expected in Q3. The trial is "high-risk/high-reward," Rama tells investors in a research note. The analyst says he's taking a "very conservative" approach for zorblisa with $300M in peak sales and a 40% probability of success. Rama believes the stock at current levels reflects no value for zorblisa. On positive data, Amicus shares have the potential to double, Rama writes. On negative data, he sees only "sentiment based" downside of 5%-15%. The analyst keeps an Overweight rating on Amicus with a $13 price target.